Price
No data yet.
Social Signal Score
Revenue
$7.67MAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Olivier Taelman
- Sector
- Healthcare
- Industry
- Medical - Specialties
- Employees
- 154
- Beta
- 0.96
- Country
- BE
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- -2.97
Financials
Revenue
$7.67M+22146.4%Net Income
$-32.96MEBITDA
$-19.41MFree Cash Flow
$-17.86MEPS (diluted)
$-0.58Shares Outstanding (diluted)
57.01M+283.2%Operating Expenses
$25.16MCash & Debt
$97.78MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $10.02M | $-90.08M | $-2.36 |
| 2024 | $4.52M | $-59.24M | $-1.81 |
| 2023 | $4.35M | $-43.21M | $-1.55 |
| 2022 | $3.08M | $-31.23M | $-1.21 |
| 2021 | $852.0K | $-27.62M | $-1.16 |
| 2020 | $69.0K | $-12.24M | $-0.68 |
| 2019 | $0.00 | $-8.45M | $-0.39 |
| 2018 | $0.00 | $-9.08M | $-0.43 |
| 2017 | $0.00 | $-10.37M | $-0.50 |
Valuation
NYXHhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
118Social Signal Score
Mentions (2)
- Newsglobenewswire.com·12h ago·Positive
…h Institute, en tant qu'Investigateur Principal du site Mont-Saint-Guibert, Belgique - 7 septembre 2026, 22h05 CET / 16h05 ET - Nyxoah SA (Euronext Bruxelles/Nasdaq: NYXH) (« Nyxoah » ou la « Société »), une société de technologies médicales qui développe des alternatives thérapeutiques révolutionnaires pour l'Apnée Obstructive du Sommeil (AOS) par neuromodulation, a annoncé aujourd'hui que le premier patient a été implanté dans BREATHE, l'étude post-approbation américaine du système Genio menée…
View source ↗ - Newsglobenewswire.com·12h ago·Positive
Nyxoah Announces First Patient Implanted in BREATHE, the U.S. Post-Approval Study of the Genio® System Nyxoah Announces First Patient Implanted in BREATHE, the U.S. Post-Approval Study of the Genio ® System
View source ↗
Earnings
Thu, Nov 5(in 8 weeks)
Consensus estimate $-0.35 per share
Typical surprise -6.5% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 5$-0.67 vs $-0.47miss
- Tue, May 12$-0.43 vs $-0.54beat
- Thu, Mar 19$-0.68 vs $-0.65miss
- Thu, Nov 13$-0.74 vs $-0.61miss
- Mon, Aug 18$-0.63 vs $-0.62miss
- Wed, May 14$-0.63 vs $-0.49miss
Estimates and results for NYXH via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.